Author: Sihan Meng,Leyu Zhu,Pengcheng Shi
Affiliation: RSBM
Email: pengchengshi@biotechrs.com; pcspc9@gmail.com
Abstract
Oral dissolving films (ODFs) have become an attractive platform for nutraceuticals, OTC medicines, cosmetics, and specialty actives, but many brands struggle to move from concept to market because traditional minimum order quantities (MOQs), tooling costs, and long lead times suppress experimentation. This paper describes how small pilot batches and structured rapid prototyping frameworks can unlock faster innovation, de-risk scale-up, and create commercial advantage—without compromising GMP, quality, or economics. We outline a modular development model covering formulation screening, design of experiments (DoE), pilot coating and packaging, stability snapshots, and market-test batches. Key measures include speed-to-decision, technical success rate, yield, and conversion of prototypes into launched SKUs. Well-designed low-MOQ programs are shown to reduce early-stage risk, align technical attributes with brand claims, and accelerate path-to-revenue for ODF products. [1–5]
Introduction
ODFs offer:
Differentiated formats for actives in sleep, energy, immune support, beauty, sexual health, pediatrics, and pet care,
Strong visual branding potential,
Convenient, water-free dosing and fast disintegration. [1,2]
However, brand owners and innovators face several barriers:
High MOQ for commercial runs (millions of doses) before market validation,
Long development cycles tied to rigid validation approaches,
Fear of formulation lock-in and sunk cost if consumer response is uncertain.
As a result, many promising ODF concepts stall at the “pitch deck” or lab sample stage.
A small MOQ + rapid prototyping model, anchored in robust technical and quality frameworks, allows:
Realistic samples for sensory, stability, and market testing,
Agile iteration on flavor, dose, and packaging,
Early identification of “winners” for full-scale validation investment.
This paper provides a practical blueprint for such programs in a way that is compatible with GMP expectations and scalable manufacturing.
Methods
1. Rapid Prototyping Framework
The proposed framework is structured in tiers:
Concept Feasibility (Bench Scale)
Solubility and compatibility of active(s),
Film-forming behavior,
Basic taste and disintegration.
Small lab casts (e.g., A4 sheets) to assess:
Output: short-list of 2–5 viable formulations per concept.
Pilot Film Batches (Pre-Commercial Scale)
Same coating mechanism as production,
Representative drying, slitting, and pouching.
Use pilot or reduced-width commercial line with:
Typical batch sizes: from a few thousand to tens of thousands of strips.
Multiple variants per run (e.g., different flavors, doses, sweeteners).
Market-Ready Validation Pathway
Refined formulation,
Formal stability initiation,
Scale-up plans and PPQ strategy.
For selected winners:
2. Process & Equipment Considerations
To enable low MOQs efficiently:
Modular setup:
Quick-change coating heads, lanes, and die-cut tools,
Standardized sachet formats and artwork templates.
Platform formulations:
Base matrices (e.g., caffeine/energy, melatonin/sleep, vitamin/immune) that can be adjusted with minimal re-validation.
Lean cleaning & changeover:
Validated cleaning procedures enabling rapid switch between SKUs.
Data capture:
Even pilot runs follow defined process parameters (coating weight, dryer temperatures, tension, seal integrity).
3. Evaluation of Pilot Batches
Each pilot batch is characterized for:
Critical Quality Attributes (CQAs):
Assay and content uniformity,
Disintegration time,
Mechanical integrity,
Organoleptic profile. [1,3]
Mini-stability (“stability snapshot”):
Short-term storage at relevant conditions (e.g., 25°C/60% RH, 40°C/75% RH for 1–3 months) to detect early degradation or packaging mismatch.
User/Market Feedback:
Small panel testing with structured questionnaires (flavor, mouthfeel, perceived effect, branding fit).
4. Business & Operational Model
A small MOQ program is shaped by:
Tiered pricing for pilot vs commercial,
Clear boundaries: pilot batches labeled as development or limited-release where applicable,
Defined pathway from pilot success → full GMP-commercial PPQ (so learning is retained).
Measures
To judge effectiveness of small MOQ / rapid prototyping for ODFs, the following measures are used:
Speed & Agility
Time from brief → first pilot samples (weeks).
Number of iterations achievable within a fixed development window.
Technical Success
% of concepts that pass feasibility (filmability, taste, stability snapshot).
% of pilot variants that meet predefined CQAs.
Conversion & Commercial Impact
% of pilot concepts advanced to full-scale launch.
Time from pilot selection → first commercial batch / market launch.
Quality & Compliance
Deviation rate in pilot runs vs commercial runs.
Alignment of pilot processes with eventual validated conditions.
Cost & Waste
Material consumption per concept.
Avoided cost of large failed launches due to early-stage filtering.
Results
(Representative, generalized outcomes derived from real-world models and case patterns.)
1. Faster Concept-to-Decision Cycles
Implementing structured pilot programs with low MOQs:
Reduced time from concept to “go/no-go” decision from 6–12 months to 2–4 months.
Enabled brands to compare multiple flavors, doses, and positioning claims using real product, not only mock-ups.
This speed allowed:
Seasonal or campaign-based ODF products,
Rapid response to trends (e.g., new ingredients, new health claims within regulatory boundaries).
2. Higher Technical Hit Rate
Because pilot runs mimic commercial processes:
Early identification of:
Actives prone to crystallization or instability,
Formulas requiring higher barrier packaging,
Taste issues not evident in micro-scale lab tests.
This increased the share of “scale-up ready” concepts among those carried forward, improving use of validation resources.
3. Reduced Commercial Risk
By testing with real users/retailers using pilot-made ODFs:
Weak concepts were stopped before committing to large tooling, inventory, and global artwork.
For strong performers, the pilot data fed directly into:
Stability protocols,
Process parameter ranges,
Marketing narratives rooted in actual sensory feedback.
Net effect: fewer failed big launches, more targeted investment.
4. Operational Feasibility at CDMO Level
Well-designed CDMO setups:
Used shared platform tooling while maintaining rigorous cleaning and documentation.
Demonstrated that small MOQs can coexist with GMP by:
Clear segregation of development vs commercial runs,
Defined change-control and documentation expectations,
Cost models that reward efficient scheduling and line utilization. [4,5]
Discussion
1. The Strategic Value of Small MOQs
Small MOQs are not just a “favor” to small brands; they are a strategic capability:
Enable serious A/B testing of concepts (e.g., melatonin-only vs melatonin + theanine ODFs) without overextending.
Support co-creation with key accounts (retailers, influencers, clinics) using real product.
Allow regional customization (flavor, language, claims) validated via local pilot batches.
For the manufacturer, this pipeline:
Feeds a steady flow of candidates into full-scale production,
Positions them as innovation partners rather than commodity suppliers.
2. Ensuring Scientific & Regulatory Rigor
“Rapid” must not mean “reckless”:
Pilot batches should follow controlled processes, traceability, and basic QC.
Claims discussed at pilot stage must anticipate regulatory boundaries for the final market.
For transitions to medicinal ODFs or higher-risk actives, early consideration of:
Stability, bioavailability, and dose accuracy under stricter GMP,
IQ/OQ/PQ and PPQ requirements,
Clinical evidence gaps.
A quality-by-design mindset ensures pilot learnings directly support later regulatory submissions, where needed. [3]
3. Scalable Platform Design
Key enablers of sustainable rapid prototyping:
Platform film bases (sleep, energy, immune, beauty, kids, etc.) with known behavior.
Standard pack formats and barrier specs to avoid re-qualifying every detail.
Digital recipe and documentation management so moving from development batch to validation protocol is incremental, not from scratch.
This platform approach turns small MOQs into a structured innovation engine.
4. When Not to Use Tiny Batches
Very small runs may be misleading if:
The process conditions differ significantly from commercial equipment.
Manual operations dominate, hiding scale-dependent defects.
Data from pilot runs are over-interpreted as clinical or long-term evidence.
To avoid this, pilot conditions should be as representative as feasible, and their limitations clearly documented.
Conclusion
Small MOQs and rapid pilot batches, when executed with technical discipline, can have a big impact on ODF innovation:
Accelerating concept testing and flavor/dose optimization,
Improving technical success rates,
Reducing commercial and regulatory risk,
Building stronger, more collaborative relationships between brands and manufacturers.
By integrating platform formulations, flexible equipment, robust QC, and clear pathways from pilot to commercial validation, ODF developers can turn agility into a long-term competitive advantage—bringing better products to market faster and smarter.
References
[1] Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009.
[2] Preis M, Woertz C. Oromucosal films as versatile dosage forms. J Pharm Pharmacol.
[3] ICH Q8(R2), Q9, Q10. Pharmaceutical Development; Quality Risk Management; Pharmaceutical Quality System.
[4] ISPE. Baseline Guides on commissioning, qualification, and technology transfer.
[5] Industry case studies on CDMO-led rapid prototyping and small-batch commercialization in ODFs and thin films (various sources).